Natural Product (NP) Details
| General Information of the NP (ID: NP6764) | |||||
|---|---|---|---|---|---|
| Name |
Beta asarone
|
||||
| Synonyms |
beta-Asarone; 5273-86-9; cis-Isoelemicin; cis-Isoasarone; (Z)-Asarone; cis-Asarone; UNII-IGA3MH6IUW; Cis-Asaron; 1,2,4-trimethoxy-5-[(Z)-prop-1-enyl]benzene; IGA3MH6IUW; (Z)-5-Propenyl-1,2,4-trimethoxybenzene; CHEBI:10353; (Z)-1,2,4-Trimethoxy-5-(1-propenyl)benzene; BENZENE, 1,2,4-TRIMETHOXY-5-PROPENYL-, (Z)-; cis-2,4,5-Trimethoxy-1-propenylbenzene; beta-asaron; CCRIS 1592; .beta.-Asarone; EINECS 226-096-6; 2,4,5-Trimethoxypropen-1-ylbenzene; cis-.beta.-Asarone; I(2)-Asarone; BRN 1910605; 1,2,4-Trimethoxy-5-((Z)-1-propenyl)benzene; (Z)-.beta.-Asarone; AI3-36897; Benzene, 1,2,4-trimethoxy-5-(1-propenyl)-, (Z)-; 3-06-00-06440 (Beilstein Handbook Reference); SCHEMBL528747; CHEMBL477752; CHEBI:68146; CHEBI:78308; cis-2,4,5-trimethoxyphenylpropene; DTXSID601020057; HMS3886B18; BCP23722; HY-N1501; MFCD00009281; s9118; ZINC13424754; AKOS030524038; CCG-266642; CS-W009103; DS-9662; L986; (Z)-1-(2,4,5-Trimethoxyphenyl)-1-propene; 1,2,4-trimethoxy-5-(prop-1-en-1-yl)benzene; C10430; cis-2,4,5-Trimethoxy-1-propenylbenzene, 70%; 1,2,4-Trimethoxy-5-[(1Z)-1-propenyl]benzene; W-105801; 1,2,4-trimethoxy-5-[(1Z)-prop-1-en-1-yl]benzene; beta-Asarone, primary pharmaceutical reference standard; Q27089385; 1,2,4-Trimethoxy-5-((z)-1-propenyl)benzene, ?-asarone; (z)-1 pound not2 pound not4-trimethoxy-5-(1-propenyl)benzene; Benzene, 1,2,4-trimethoxy-5-(1-propenyl)-, (Z)- (9CI)
Click to Show/Hide
|
||||
| Species Origin | Acorus tatarinowii ... | Click to Show/Hide | |||
| Acorus tatarinowii | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C12H16O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC=CC1=CC(=C(C=C1OC)OC)OC
|
||||
| InChI |
1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5-
|
||||
| InChIKey |
RKFAZBXYICVSKP-WAYWQWQTSA-N
|
||||
| CAS Number |
CAS 5273-86-9
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [1] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CYB5R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | ||
| SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
| MKN74 | CVCL_2791 | Gastric tubular adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The increase of chemotherapy sensitization by Beta-asarone is associated with the inhibition of tumor glycolysis. | |||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
| Experimental
Result(s) |
Beta-asarone could promote the entry of TMZ into U252 cells through the membrane. | |||||
